P Pharma Mar SA
P
Avatud
99 5.54
Ülevaade
Aktsiahinna muutus
24h
Min
92.15
Max
98.8
Sissetulek | -58M 1.6M |
|---|---|
Müük | -48M 43M |
P/E Sektori keskmine | 21.191 49.888 |
Aktsiakasum | 0.088 |
Kasumimarginaal | 3.725 |
Töötajad | 505 |
EBITDA | -40M 2.7M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +27.25% upside |
Järgmine tulemuste avaldamine | 29. juuli 2026 |
|---|
Turukapital | 40M 1.7B |
|---|---|
Eelmine avamishind | 93.46 |
Eelmine sulgemishind | 99 |
Pharma Mar SA Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Pharma Mar SA Prognoos
Hinnasiht
By TipRanks
27.25% tõus
12 kuu keskmine prognoos
Keskmine 120.502 EUR 27.25%
Kõrge 121 EUR
Madal 120 EUR
Põhineb 2 Wall Streeti analüütiku instrumendi Pharma Mar SA 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
